Figure 3.

mPGES-1 null mice exhibit reduced inflammation in response to bleomycin treatment. (a) Immunofluorescence staining was performed with MOMA-2 antibody (a marker of macrophages) to account for inflammation in response to bleomycin treatment (4-week bleomycin treatment). (b) mPGES-1 null mice showed a marked reduction in the number of macrophages compared with the control mice in response to bleomycin. *P < 0.05; bleomycin-treated wild-type (WT) and mPGES-1 null mice compared with phosphate-buffered saline (PBS)-treated mice. +P < 0.05, bleomycin-treated mPGES-1 null mice compared with bleomycin-treated WT mice. Representative data from four separate animals per group are shown. (c) Hematoxylin and eosin (H&E)-stained sections were further scored in a blinded fashion to account for inflammation as described in Materials and methods. mPGES-1 null mice showed a reduced inflammation score compared with WT mice in response to bleomycin. *P < 0.05; bleomycin-treated WT and mPGES-1 null mice compared with PBS-treated mice. +P < 0.05; bleomycin-treated mPGES-1 null mice compared with bleomycin-treated WT mice. Representative data from four separate animals per group are shown. MOMA-2, monocyte + macrophage marker; mPGES-1, microsomal prostaglandin E2 sythnase-1.

McCann et al. Arthritis Research & Therapy 2011 13:R6   doi:10.1186/ar3226
Download authors' original image